Fact CheckerSign in

NCT04844060Recruiting

Cerebro Spinal Fluid Collection (CSF)

Analysis of Clinical Data and Diagnosis in Any Person Requiring an Assay of Alzheimer Biomarkers in Cerebrospinal Fluid

Source: ClinicalTrials.gov · Last updated 27 Apr 2023 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Cognitive neurodegenerative diseases are a major public health issue. At present, the diagnosis of certainty is still based on anatomopathological analyses. Even if the diagnostic tools available to clinicians have made it possible to improve probabilistic diagnosis during the patient's lifetime, there are still too many diagnostic errors and sub-diagnostic in this field. The arrival of biomarkers has made it possible to reduce these diagnostic errors, which were of the order of 25 to 30%. This high error rate is due to different parameters. These diseases are numerous and often present common symptoms due to the fact that common brain structures are affected. These diseases evolve progressively over several years and their early diagnosis, when the symptoms are discrete, makes them even more difficult to diagnose at this stage. In addition, co-morbidities are common in the elderly, further complicating the diagnosis of these diseases. At present, the only cerebrospinal fluid (CSF) biomarkers that are routinely used for the biological diagnosis of neurodegenerative cognitive pathologies are those specific to Alzheimer's disease: Aβ42, Aβ40, Tau-total and Phospho-Tau. These biomarkers represent an almost indispensable tool in the diagnosis of dementia. It is therefore important to determine whether Alzheimer's biomarkers can be disrupted in other neurodegenerative cognitive pathologies, but also to find biomarkers specific to these different pathologies by facilitating the implementation of clinical studies which will thus make it possible to improve their diagnosis.

Status (registry)
Recruiting
Study type
Observational
Enrollment
10000 (estimated)
First submitted
29 Mar 2021
Start date
1 Feb 2010
Primary completion date
31 Dec 2030
Lead sponsor
University Hospital, Strasbourg, France
NCT number
NCT04844060

What you commit to

  • Study type: Observational
  • Planned participants: 10000
  • From 1 Feb 2010 to the primary completion date, 31 Dec 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients who do not have a lumbar puncture
  • Patients for whom no accurate diagnostic information is available

Who the study is looking for

  • Patients with lumbar puncture (LP)
  • Patients with accurate clinical diagnosis

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Service d'évaluation et Centre Mémoire de Ressources et de Recherche (CM2R), Hôpital de jour Saint François - Pôle de Gériatrie, Hôpitaux Universitaires de Strasbourg, Hôpital de la Robertsau
Coordinator of this site? Confirm its status
StrasbourgFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.